Ratings for Alnylam Pharmaceuticals ALNY -1.28% Get Free Report were provided by 18 analysts in the past three months, ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

After over a decade of research, Onpattro, the first RNAi therapy, was approved in 2018 for polyneuropathy in hereditary ATTR amyloidosis. This positioned Alnylam as a leader among RNA-based ...

The company received a complete response letter (CRL) from the FDA for their drug Onpattro in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Consequently, Alnylam Pharma has ...

As Alnylam’s second-generation RNA interference therapy, Amvuttra, nears its own phase 3 readout in ATTR-CM, the company said it has decided not to pursue any additional indications for Onpattro ...

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated.

Onpattro is the first and only FDA-approved treatment for this indication. Year to date, shares of Alnylam have declined 10.9% compared with the industry’s 13.1% fall. Zacks Investment Research ...

Alnylam Pharmaceuticals ... Patisiran is the established name for ONPATTRO ®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis ...

The company reported preliminary net product revenues for its portfolio of marketed drugs – Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari (givosiran) and Oxlumo (lumasiran). Alnylam's ...